We are live on ! Find out more
AVEO

AVEO Pharmaceuticals, Inc.
AVEO

Delisted

AVEO was delisted on the 19th of January, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in AVEO Pharmaceuticals, Inc. in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 110 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 110 → 0 (-110)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $368M → $0 (-$368M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 110

Holders
–
Holders Change
-110
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
110
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$22.6M
2
NAM
Nexpoint Asset Management
Texas
-$21.9M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$21.6M
4
AllianceBernstein
AllianceBernstein
Tennessee
-$20.1M
5
Man Group
Man Group
United Kingdom
-$19.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
76
Credit Suisse
Switzerland
– -$343K -22,966 Closed
Bank of America
77
Bank of America
North Carolina
– -$327K -21,854 Closed
BOCH
78
Blue Owl Capital Holdings
New York
– -$315K -21,009 Closed
WAM
79
Wolverine Asset Management
Illinois
– -$300K -20,076 Closed
LP
80
LMR Partners
United Kingdom
– -$252K -16,880 Closed
CM
81
Crystalline Management
Canada
– -$235K -15,740 Closed
JRP
82
Jasper Ridge Partners
California
– -$233K -15,575 Closed
B
83
Bailard
California
– -$227K -15,200 Closed
JC
84
JBF Capital
Colorado
– -$209K -14,000 Closed
GC
85
Guggenheim Capital
Illinois
– -$207K -13,849 Closed
LIP
86
Lighthouse Investment Partners
Florida
– -$206K -13,754 Closed
Charles Schwab
87
Charles Schwab
California
– -$167K -11,178 Closed
MFS
88
Mirabella Financial Services
United Kingdom
– -$167K -11,154 Closed
BBWP
89
Beacon Bridge Wealth Partners
Pennsylvania
– -$150K -10,000 Closed
VIA
90
Virtus Investment Advisers
Connecticut
– -$140K -9,362 Closed
TRCT
91
Tower Research Capital (TRC)
New York
– -$130K -8,703 Closed
Legal & General Group
92
Legal & General Group
United Kingdom
– -$123K -8,252 Closed
Lazard Asset Management
93
Lazard Asset Management
New York
– -$112K -7,542 Closed
Zurich Cantonal Bank
94
Zurich Cantonal Bank
Switzerland
– -$95.8K -6,409 Closed
SAM
95
Shell Asset Management
Netherlands
– -$46K -3,082 Closed
Deutsche Bank
96
Deutsche Bank
Germany
– -$35.4K -2,368 Closed
SFG
97
Steward Financial Group
Texas
– -$29K -2,000 Closed
BAM
98
Belpointe Asset Management
Nevada
– -$14.9K -1,000 Closed
Citigroup
99
Citigroup
New York
– -$11.6K -775 Closed
Osaic Holdings
100
Osaic Holdings
Arizona
– -$9K -566 Closed
1 2 3
4
5

AVEO Hedge Fund Activity: Q1 2023 in Review

0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q1 2023, worth a combined $0 — down 100% from $368M a quarter earlier.

Sellers outnumbered buyers: 110 funds closed out of AVEO and 0 opened new positions — a net loss of 110 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $22.6M sold.

  • 0 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q1 2023, down from 110 in Q4 2022.
  • Funds reported $0 of AVEO Pharmaceuticals, Inc. stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new AVEO Pharmaceuticals, Inc. positions in Q1 2023 and 110 closed out, a net change of -110 holders.
  • The largest AVEO Pharmaceuticals, Inc. seller in Q1 2023 was Vanguard Group, an estimated $22.6M sold.

Based on aggregated 13F filings for Q1 2023.